
TRETINOIN - tretinoin cream TRETINOIN - tretinoin gel Physicians Total Care, Inc.

TRETINOIN CREAM TRETINOIN GEL - FOR TOPICAL USE ONLY

Description:

Tretinoin Cream and Tretinoin Gel are used for the topical treatment of acne vulgaris. Tretinoin Gel contains tretinoin (retinoic acid, vitamin A acid) in either of two strengths, 0.025% or 0.01% by weight, in a gel vehicle of butylated hydroxytoluene, hydroxypropyl cellulose and alcohol (denatured with *tert*-butyl alcohol and brucine sul-fate) 90% w/w. Tretinoin Cream contains tretinoin in either of three strengths, 0.1%, 0.05%, or 0.025% by weight, in a hydrophilic cream vehicle of stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. Chemically, tretinoin is *all-trans*-retinoic acid and has the following structure:



Clinical Pharmacology:

Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.

Indications and Usage:

Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Contraindications:

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

Precautions:

General:

If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is

recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

Drug Interactions:

Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to "rest" a patient's skin until the effects of such preparations subside before use of tretinoin is begun.

Carcinogenesis:

Long-term animal studies to determine the carcinogenic potential of tretinoin have not been performed. Studies in hairless albino mice suggest that tretinoin may accelerate the tumorigenic potential of weakly carcinogenic light from a solar simulator. In other studies, when lightly pigmented hairless mice treated with tretinoin were exposed to carcinogenic doses of UVB light, the incidence and rate of development of skin tumors was reduced. Due to significantly different experimental conditions, no strict comparison of these disparate data is possible. Although the significance of these studies to man is not clear, patients should avoid or minimize exposure to sun.

Pregnancy:

Teratogenic effects. Pregnancy Category C. <u>Oral</u> tretinoin has been shown to be teratogenic in rats when given in doses 1000 times the topical human dose. Oral tretinoin has been shown to be fetotoxic in rats when given in doses 500 times the topical human dose. <u>Topical</u> tretinoin has not been shown to be teratogenic in rats and rabbits when given in doses of 100 and 320 times the topical human dose, respectively (assuming a 50 kg adult applies 250 mg of 0.1% cream topically). However, at these topical doses, delayed ossification of a number of bones occurred in both species. These changes may be considered variants of normal development and are usually corrected after weaning. There are no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman.

GELS ARE FLAMMABLE. Note: Keep away from heat and flame. Keep tube tightly closed.

Adverse Reactions:

The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see **Dosage and Adminis tration:** Section).

Overdosage:

If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.

Dosage and Administration:

Tretinoin Cream or Tretinoin Gel should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Gel: Excessive application results in "pilling" of the gel, which minimizes the likelihood of over application by the patient.

Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance.

During the early weeks of therapy, an *apparent* exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.

Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen.

Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms.

Patients treated with tretinoin acne treatment may use cosmetics, but the area to be treated should be cleansed thoroughly before the medication is applied. (see **Precautions**.)

How Supplied:

Tretinoin is supplied as:

Tretinoin Cream		
Strength	Quantity	NDC Code
0.025% Cream	20 g	NDC 54868-4126-0
0.025% Cream	45 g	NDC 54868-4126-1
0.05% Cream	20 g	NDC 54868-4378-0
0.05% Cream	45 g	NDC 54868-4378-1
	_	
0.1% Cream	20 g	NDC 54868-4379-1
0.1% Cream	45 g	NDC 54868-4379-0
	C	
Tretinoin Gel		
Strength	Quantity	NDC Code
0.025% Gel	15 g	NDC 54868-4444-1

Tretinoin Gel, 0.025% and 0.01%: store below 86°F. Tretinoin Cream, 0.1%, 0.05%, and 0.025%: store below 80°F. **Rx Only** Manufactured by: Ortho Pharmaceutical a division of Janssen Ortho LLC Manati, Puerto Rico 00674-0463 Distributed by: PERRIGO ALLEGAN, MI 49010 Rev. 11/09 0A400RCJ3 30008761 10066102

Additional barcode labeling by: Physicians Total Care, Inc. Tulsa, Oklahoma 74146

PATIENT INSTRUCTIONS

TRETINOIN CREAM

TRETINOIN GEL

Acne Treatment

PATIENT INSTRUCTIONS

For Topical Use Only

IMPORTANT

Read Directions Carefully Before Using

THIS LEAFLET TELLS YOU ABOUT TRETINOIN ACNE TREATMENT AS PRESCRIBED BY YOUR PHYSICIAN. THIS PRODUCT IS TO BE USED ONLY ACCORDING TO YOUR DOCTOR'S INSTRUCTIONS, AND IT SHOULD NOT BE APPLIED TO OTHER AREAS OF THE BODY OR TO OTHER GROWTHS OR LESIONS. THE LONG-TERM SAFETY AND EFFECTIVENESS OF THIS PRODUCT IN OTHER DISORDERS HAVE NOT BEEN EVALUATED. IF YOU HAVE ANY QUESTIONS, BE SURE TO ASK YOUR DOCTOR.

WARNINGS AND PRECAUTIONS

The effects of the sun on your skin. As you know, overexposure to natural sunlight or the artificial sunlight of a sunlamp can cause sunburn. Overexposure to the sun over many years may cause premature aging of the skin and even skin cancer. The chance of these effects occurring will vary depending on skin type, the climate and the care taken to avoid overexposure to the sun. Therapy with tretinoin may make your skin more susceptible to sunburn and other adverse effects of the sun, so unprotected exposure to natural or artificial sunlight should be minimized.

Laboratory findings.*When laboratory mice are exposed to artificial sunlight, they often develop skin tumors. These sunlight-induced tumors may appear more quickly and in greater number if the mouse is also*

topically treated with the active ingredient in Tretinoin Cream and Gel, tretinoin. In some studies, under different conditions, however, when mice treated with tretinoin were exposed to artificial sunlight, the incidence and rate of development of skin tumors was reduced. There is no evidence to date that tretinoin alone will cause the development of skin tumors in either laboratory animals or humans. However, investigations in this area are continuing.

Use caution in the sun. When outside, even on hazy days, areas treated with tretinoin should be protected. An effective sunscreen should be used <u>any time you are outside</u> (consult your physician for a recommendation of an SPF level which will provide you with the necessary high level of protection). For extended sun exposure, protective clothing, like a hat, should be worn. Do not use artificial sunlamps while you are using tretinoin. If you do become sunburned, stop your therapy with tretinoin until your skin has recovered.

Avoid excessive exposure to wind or cold. Extremes of climate tend to dry or burn normal skin. Skin treated with tretinoin may be more vulnerable to these extremes. Your physician can recommend ways to manage your acne treatment under such conditions.

Possible problems. The skin of certain sensitive individuals may become excessively red, swollen, blistered or crusted. If you are experiencing severe or persistent irritation, discontinue the use of tretinoin and consult your physician. There have been reports that, in some patients, areas treated with tretinoin developed a temporary increase or decrease in the amount of skin pigment (color) present. The pigment in these areas returned to normal either when the skin was allowed to adjust to tretinoin or therapy was discontinued.

Use other medication only on your physician's advice. Only your physician knows which other medications may be helpful during treatment and will recommend them to you if necessary. Follow the physician's instructions carefully. In addition, you should avoid preparations that may dry or irritate your skin. These preparations may include certain astringents, toiletries containing alcohol, spices or lime, or certain medicated soaps, shampoos and hair permanent solutions. Do not allow anyone else to use this medication.

Do not use other medications with tretinoin which are not recommended by your doctor. The medications you have used in the past might cause unnecessary redness or peeling.

If you are pregnant, think you are pregnant or are nursing an infant: No studies have been conducted in humans to establish the safety of tretinoin in pregnant women. If you are pregnant, think you are pregnant, or are nursing a baby, consult your physician before using this medication.

GELS ARE FLAMMABLE. Note: Keep away from heat and flame. Keep tube tightly closed.

AND WHILE YOU'RE ON TRETINOIN THERAPY

Use a mild, non-medicated soap. Avoid frequent washings and harsh scrubbing. Acne isn't caused by dirt, so no matter how hard you scrub, you can't wash it away. Washing too frequently or scrubbing too roughly may at times actually make your acne worse. Wash your skin gently with mild, bland soap. Two or three times a day should be sufficient. Pat skin dry with a towel. Wait 20 to 30 minutes before applying tretinoin. Remember, excessive irritation such as rubbing, too much washing, use of other medications not suggested by your physician, etc., may worsen your acne.

HOW TO USE TRETINOIN

To get the best results with Tretinoin therapy, it is necessary to use it properly. Forget about the instructions given for other products and the advice of friends. Just stick to the special plan your doctor has laid out for you and be patient. Remember, when Tretinoin is *used properly*, many users see improvement by 12 weeks. AGAIN, FOLLOW INSTRUCTIONS - BE PATIENT – DON'T START AND STOP THERAPY ON YOUR OWN - IF YOU HAVE QUESTIONS, ASK YOUR DOCTOR.

To help you use the medication correctly, keep these simple instructions in mind.



- Apply tretinoin once daily before bedtime, or as directed by your physician. Your physician may advise, especially if your skin is sensitive, that you start your therapy by applying tretinoin every other night. First, wash with a mild soap and dry your skin gently. WAIT 20 to 30 MINUTES BEFORE APPLYING MEDICATION; it is important for skin to be completely dry in order to minimize possible irritation.
- It is better not to use more than the amount suggested by your physician or to apply more frequently than instructed. Too much may irritate the skin, waste medication and won't give faster or better results.
- Keep the medication away from the corners of the nose, mouth, eyes and open wounds. *Spread away from these areas when applying*.
- *Cream:* Squeeze about a half inch or less of medication onto the fingertip. While that should be enough for your whole face, after you have some experience with the medication you may find you need slightly more or less to do the job. The medication should become invisible almost immediately. If it is still visible, you are using too much. Cover the affected area lightly with Tretinoin Cream by first dabbing it on your forehead, chin and both cheeks, then spreading it over the entire affected area. Smooth gently into the skin.
- *Gel:* Squeeze about a half inch or less of medication onto the fingertip. While that should be enough for your whole face, after you have some experience with the medication you may find you need slightly more or less to do the job. The medication should become invisible almost immediately. If it is still visible, or if dry flaking occurs from the gel **within a minute or so**, you are using too much. Cover the affected area lightly with Tretinoin Gel by first dabbing it on your forehead, chin and both cheeks, then spreading it over the entire affected area. Smooth gently into the skin.
- It is recommended that you apply a moisturizer or a moisturizer with sunscreen that will not aggravate your acne (noncomedogenic) every morning after you wash.

WHAT TO EXPECT WITH YOUR NEW TREATMENT

Tretinoin works deep inside your skin and this takes time. You cannot make tretinoin work any faster by applying more than one dose each day, but an excess amount of tretinoin may irritate your skin. Be patient.

There may be some discomfort or peeling during the early days of treatment. Some patients also notice that their skin begins to take on a blush.

These reactions do not happen to everyone. If they do, it is just your skin adjusting to Tretinoin and this usually subsides within two to four weeks. These reactions can usually be minimized by following instructions carefully. Should the effects become excessively troublesome, consult your doctor.

BY THREE TO SIX WEEKS, some patients notice an appearance of new blemishes (papules and pustules). At this stage it is *important to continue* using tretinoin.

If tretinoin is going to have a beneficial effect for you, you should notice a continued improvement in your appearance after 6 to 12 weeks of therapy. Don't be discouraged if you see no immediate improvement. Don't stop treatment at the first signs of improvement.

Once your acne is under control you should continue regular application of tretinoin until your physician instructs otherwise.

IF YOU HAVE QUESTIONS

All questions of a medical nature should be taken up with your doctor.

Manufactured by: Ortho Pharmaceutical

a division of Janssen Ortho LLC

Manati, Puerto Rico 00674-0463

Distributed by:

PERRIGO

ALLEGAN, MI 49010


Rev. 11/09

0A400RCJ3

30008761 10066102

Principal Display Panel - Tretinoin Cream, 0.025%

Tretinoin Cream, 0.025% For Topical Use Only. Dosage: See package insert. Store below 80°F. Warning: Keep out of reach of children. Rx Only




Principal Display Panel - Tretinoin Cream, 0.05%

Tretinoin Cream, 0.05%

For Topical Use Only. Dosage: See package insert.

Store below 80°F. Warning: Keep out of reach of children.

Rx Only




Principal Display Panel - Tretinoin Cream, 0.1%

Tretinoin Cream, 0.1%

For Topical Use Only. Dosage: See package insert.

Store below 80°F. Warning: Keep out of reach of children.

Rx Only




Principal Display Panel - Tretinoin Gel, 0.025%

Tretinoin Gel, 0.025%

For Topical Use Only. Dosage: See package insert.

Store below 86°F. Warning: Keep out of reach of children.

Rx Only



TRETINOIN					
tretinoin cream					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code ((Source)	NDC:54868-41	26(NDC:45802-182)
Route of Administration	TOPICAL				
Active Ingredient/Active Moi	ety				
Ingre	dient Name		Basis o	of Strength	Strength
TRETINO IN (UNII: 5688UTC01R) (TRE	TINOIN - UNII:5688UTC01R)		TRETINOI	Ν	0.025 mg in 1 g
Inactive Ingredients					

	Ingredient Nam	e	Strength			
STEARIC ACID (UNII: 4EL)	/7Z65AP)					
ISOPROPYL ALCOHOL (UNII: ND2M416302)						
POLYOXYL 40 STEARATE (UNII: 13A4J4NH9I)						
STEARYL ALCOHOL (UN	II: 2KR89I4H1Y)					
XANTHAN GUM (UNII: TTV	/12P4NEE)					
SORBIC ACID (UNII: X045	WJ989B)					
BUTYLATED HYDRO XYT	OLUENE (UNII: 1P9D0Z171K)					
WATER (UNII: 059QF0KO	R)					
Packaging						
# Item Code	Package Description	Marketing Start Date	Marketing End Date			

# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:54868-4126-0	1 in 1 CARTON		
1	20 g in 1 TUBE		
2 NDC:54868-4126-1	1 in 1 CARTON		
2	45 g in 1 TUBE		

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANDA	ANDA0 19 0 49	05/09/2005			

TRETINOIN					
tretinoin cream					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (S	Source)	NDC:54868-437	78(NDC:45802-36
Route of Administration	TOPICAL				
Active Ingredient/Active M	oiety				
Ing	gredient Name		Basis	of Strength	Strength
TRETINO IN (UNII: 5688UTC01R) (FRETINOIN - UNII:5688UTC01R)		TRETINO	IN	0.05 mg in 1 g
Inactive Ingredients					
	Ingredient Name				Strength
STEARIC ACID (UNII: 4ELV7Z65A)	0				Strength
STEARIC ACID (UNII: 4ELV7Z65AI ISOPROPYL ALCOHOL (UNII: NE)				Strength
	2M416302)				Strength
ISOPROPYL ALCOHOL (UNII: NE) 2M416302) 13A4J4NH9I)				Strength
ISOPROPYL ALCOHOL (UNII: NE POLYOXYL 40 STEARATE (UNII:	2M416302) 13A4J4NH9I) 9I4H1Y)				Strength
ISOPROPYL ALCOHOL (UNII: NE POLYOXYL 40 STEARATE (UNII: STEARYL ALCOHOL (UNII: 2KR8	2M416302) 13A4J4NH9I) 9I4H1Y) E)				Strength
ISOPROPYL ALCOHOL (UNII: NE POLYOXYL 40 STEARATE (UNII: STEARYL ALCOHOL (UNII: 2KR8 XANTHAN GUM (UNII: TTV12P4NE	2M416302) 13A4J4NH9I) 9I4H1Y) E)				Strength

Packaging								
# Item Code	Pac	kage Description	Marketi	ng Star	t Date	Ma	arketi	ng End Date
1 NDC:54868-4378-0	1 in 1 CA			0				0
1	20 g in 1	TUBE						
2 NDC:54868-4378-1	1 in 1 CA	RTON						
2	45 g in 1	TUBE						
Marketing Info	rmation							
Marketing Category	Applicatio	on Number or Monogra	ph Citation	Mark	eting Sta	rt Date	Mark	keting End Dat
ANDA	ANDA0 17522			06/16/2	005			
FRETINOIN								
retinoin cream								
Product Informati								
	on							
	on	HIIMAN PRESCRIPTION	DRUG Item	Code (Si	ource) I	NDC ·54868	8-4379	(NDC ·45802-18
Product Type Route of Administrat		HUMAN PRESCRIPTION	DRUG Item	Code (Si	ource) I	NDC:5486{	8-4379	(NDC:45802-18
Product Type	ion	TOPICAL	DRUG Item	Code (S	ource) I	NDC:54868	8-4379	(NDC:45802-18
Product Type Route of Administrat	ion 'Active Moie	TOPICAL	DRUG Item	Code (S		NDC:54868 of Stren		(NDC:45802-18 Strength
Product Type Route of Administrat Active Ingredient/	ion 'Active Moio Ingre	TOPICAL		Code (S		of Stren		
Product Type Route of Administrat Active Ingredient/	ion 'Active Moio Ingre BUTC01R) (TRE	TOPICAL ety edient Name		Code (S	Basis	of Stren		Strength
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688	ion 'Active Moio Ingre BUTC01R) (TRE	TOPICAL ety edient Name	91R)	Code (S	Basis	of Stren		Strength
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688	ion 'Active Moid Ingre BUTCO 1R) (TRE ItS	TOPICAL ety edient Name ETINOIN - UNII:5688UTCO	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredier	ion (Active Moie Ingre BUTCO 1R) (TRE hts ELV7Z65AP)	TOPICAL ety edient Name ETINOIN - UNII:5688UTCO Ingredient Name	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4	ion (Active Moie Ingre BUTC01R) (TRE BUTC01R) (TRE ELV7Z65AP) ATE (UNII: 0 REE	TOPICAL ety edient Name ETINOIN - UNII:5688UTCO Ingredient Name	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredier STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA	ion /Active Moid Ingre BUTC0 1R) (TRE BUTC0 1R) (TRE BUTC0 1R) (TRE BUTC0 1R) (TRE BUTC0 1R) (TRE ATE (UNII: 0 REE RATE (UNII: 13 A	TOPICAL ety edient Name CTINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) A4J4NH9 I)	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5684 Inactive Ingredier STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAR STEARYL ALCOHOL (ion (Active Moid Ingre BUTC01R) (TRE BUTC01R) (TRE ELV7Z65AP) NTE (UNII: 0 REE RATE (UNII: 13A (UNII: 2KR8914)	TOPICAL ety edient Name CTINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) A4J4NH9 I)	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPRO PYL MYRISTA POLYO XYL 40 STEAR STEARYL ALCOHOL (XANTHAN GUM (UNII: 1	ion (Active Moie Ingre BUTC01R) (TRE BUTC01R) (TRE BUTC01R) (TRE RATE (UNII: 0 RES RATE (UNII: 13A (UNII: 2KR8914H TTV12P4NEE)	TOPICAL ety edient Name CTINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) A4J4NH9 I)	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5683 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAF	ion (Active Moid Ingre BUTC01R) (TRE BUTC01R) (TRE BUTC01R) (TRE CONTE (UNII: 0 REE CONTE (UNII: 13A (UNII: 2KR8914H TTV12P4NEE) 045WJ989B)	TOPICAL ety edient Name TINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) AJJ4NH9I) HIY)	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAR STEARYL ALCOHOL (XANTHAN GUM (UNII: 1	ion (Active Moie Ingre 8 UTC0 1R) (TRE 8 UTC0 1R) (TRE 1ts 1ts 1ts 1ts 1ts 1ts 1ts 1ts	TOPICAL ety edient Name TINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) AJJ4NH9I) HIY)	91R)	Code (So	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAF STEARYL ALCOHOL (XANTHAN GUM (UNII: 7 SORBIC ACID (UNII: X)	ion (Active Moie Ingre 8 UTC0 1R) (TRE 8 UTC0 1R) (TRE 1ts 1ts 1ts 1ts 1ts 1ts 1ts 1ts	TOPICAL ety edient Name TINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) AJJ4NH9I) HIY)	91R)	Code (S	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAF STEARYL ALCOHOL (XANTHAN GUM (UNII: 7 SORBIC ACID (UNII: X)	ion (Active Moie Ingre 8 UTC0 1R) (TRE 8 UTC0 1R) (TRE 1ts 1ts 1ts 1ts 1ts 1ts 1ts 1ts	TOPICAL ety edient Name TINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) AJJ4NH9I) HIY)	91R)	Code (So	Basis	of Stren		Strength 0.1 mg in 1 g
Product Type Route of Administrat Active Ingredient/ TRETINO IN (UNII: 5688 Inactive Ingredien STEARIC ACID (UNII: 4 ISOPROPYL MYRISTA POLYOXYL 40 STEAF STEARYL ALCOHOL (XANTHAN GUM (UNII: 1 SORBIC ACID (UNII: XC BUTYLATED HYDROX WATER (UNII: 059QF0F	ion (Active Moid Ingre BUTC01R) (TRE BUTC01R) (TRE Its ELV7Z65AP) ATE (UNII: 0 RE8 ATE (UNII: 0 RE8 ATE (UNII: 13A (UNII: 2KR89I4H TTV12P4NEE) 045WJ989B) XTOLUENE (U XOOR)	TOPICAL ety edient Name TINOIN - UNII:5688UTCO Ingredient Name 3K4LNJS) AJJ4NH9I) HIY)	91R)		Basis	of Stren IN	g th 9	Strength 0.1 mg in 1 g

#Item CodePackage DescriptionMarketing Start DateMarketing End Date1NDC:54868-4379-101in 1 CARTON---120 g in 1 TUBE-----2NDC:54868-4379-001in 1 CARTON-----2-45 g in 1 TUBE-------

Marketing Info	rmation					
Marketing Category		on Number or Monograph Cita	ation Ma	rketing Start	Date Ma	arketing End Dat
ANDA	ANDA017340			/2008		
	1111211017010		10,1	,		
FRETINOIN						
retinoin gel						
Product Informati	on					
Product T ype		HUMAN PRESCRIPTION DRUG	Item Code	(Source) NI	DC:54868-44	444(NDC:45802-36
Route of Administrati	on	TOPICAL				
Active Ingredient/	Active Moi	ety				
		dient Name		Basis of S	trength	Strength
TRETINO IN (UNII: 5688	UTC01R) (TRE	TINOIN - UNII:5688UTC01R)		TRETINOIN		0.025 mg in 1 g
Inactive Ingredien	.15	Ingredient Name				Strength
BUTYLATED HYDROX	YTOLUENE (U					5
HYDROXYPROPYL CE	LLULOSE (UI	NII: RFW2ET671P)				
	58.V90.M					
ALCOHOL (UNII: 3K99	50 + 5 0 141)					
ALCOHOL (UNII: 3K99) TERT-BUTYL ALCOHO		3SFE959)				
TERT-BUTYL ALCOHO	DL (UNII: MD8					
TERT-BUTYL ALCOHO	DL (UNII: MD8					
TERT-BUTYL ALCOHO BRUCINE SULFATE HE	DL (UNII: MD8					
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging	DL (UNII: MD8	E (UNII: O900CDH328)	net/optimer C++	ant Data	Maule	ting End Data
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging # Item Code	DL (UNII: MD8 PTAHYDRAT	E (UNII: O900CDH328) kage Description Ma	arketing Sta	art Date	Marke	eting End Date
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging	DL (UNII: MD8 PTAHYDRAT) Pac 1 in 1 CA	E (UNII: O900CDH328) Kage Description Ma RTON	arketing Sta	art Date	Marke	eting End Date
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging Item Code NDC:54868-4444-1	DL (UNII: MD8 PTAHYDRAT	E (UNII: O900CDH328) Kage Description Ma RTON	arketing Sta	art Date	Marke	eting End Date
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging # Item Code 1 NDC:54868-4444-1	DL (UNII: MD8 PTAHYDRAT) Pac 1 in 1 CA	E (UNII: O900CDH328) Kage Description Ma RTON	arketing Sta	art Date	Marke	eting End Date
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging # Item Code 1 NDC:54868-4444-1 1	DL (UNII: MD8 PTAHYDRAT) PTAHYDRAT 1 in 1 CAI 15 g in 1 7	E (UNII: O900CDH328) Kage Description Ma RTON	arketing Sta	art Date	Marke	eting End Date
TERT-BUTYL ALCOHO BRUCINE SULFATE HE Packaging Item Code NDC:54868-4444-1	DL (UNII: MD8 PTAHYDRAT) 1 in 1 CAI 15 g in 1 7 rmation	E (UNII: O900CDH328) Kage Description Ma RTON		art Date rketing Start		eting End Date arketing End Dat

Labeler - Physicians Total Care, Inc. (194123980)

Establishment					
Name	Address	ID/FEI	Business Operations		
Physicians Total Care, Inc.		194123980	relabel		

Revised: 4/2012